Drugs & Aging

, Volume 18, Issue 4, pp 277–304 | Cite as

Tolterodine

A Review of its Use in the Treatment of Overactive Bladder
Adis Drug Evaluation

Summary

Abstract

Tolterodine is a competitive muscarinic receptor antagonist that shows in vivo selectivity for the bladder over the salivary glands compared with oxybutinin.

Results of randomised double-blind placebo-controlled studies indicate that tolterodine 4 mg/day (administered as immediate-release tablets 2mg twice daily or extended-release capsules 4mg daily) is superior to placebo in improving micturition diary variables in patients with overactive bladder. Moreover, tolterodine 2mg twice daily is as effective as oxybutynin 5mg 3 times daily. Maximum treatment effects with both drugs occurred after 5 to 8 weeks of treatment and improvements were maintained during long term treatment for up to 24 months.

In a pooled analysis of four 12-week studies, equivalent and significant reductions in micturition frequency (−2.3 and −2.0 vs −1.4, p < 0.001) and the incidence of urge incontinence episodes (−1.6 and −1.8 vs −1.1, p < 0.05) were reported for tolterodine 2mg twice daily and oxybutynin 5mg 3 times daily compared with placebo. Functional bladder capacity was also significantly increased.

Improvements in patient perceptions of their urgency symptoms and of problems caused by their bladder condition were significantly greater during treatment with tolterodine than with placebo.

Tolterodine was generally well tolerated in clinical trials of up to 24 months’ duration. Dry mouth was the most frequent adverse event. The incidence (40 vs 78%, p < 0.001) and intensity of this event was lower with tolterodine 2mg twice daily than oxybutynin 5mg 3 times daily. Additionally, a 23% lower incidence of dry mouth was reported with once daily extended-release tolterodine capsules than with twice daily immediate-release tablets (p < 0.02). The incidence of adverse CNS events with tolterodine was low and similar to that of placebo. Tolterodine was well tolerated in elderly patients and no serious tolerability concerns were identified.

Conclusions: Tolterodine is the first antimuscarinic agent to be specifically developed for the treatment of overactive bladder. The functional selectivity of tolterodine for the bladder translates into good efficacy and tolerability in patients, including the elderly, with overactive bladder. Tolterodine is as effective as oxybutynin in improving micturition diary variables but is associated with a significantly lower incidence and intensity of dry mouth. This favourable tolerability profile, together with sustained clinical efficacy during long term treatment, places tolterodine as a valuable treatment for the symptoms of overactive bladder.

Pharmacodynamic Properties

Tolterodine and its active 5-hydroxymethyl metabolite (5-HM) are potent and competitive muscarinic receptor antagonists and share a similar pharmacological profile. Neither compound showed specificity for any particular muscarinic receptor subtype in radioligand-binding studies.

Tolterodine and oxybutynin are equipotent muscarinic receptor antagonists in vitro. Carbachol-induced contractions of guinea-pig urinary bladder strips and nerve-mediated contractions of isolated human detrusor preparations were inhibited to a similar extent by tolterodine and oxybutynin.

Tolterodine and 5-HM show functional selectivity for the bladder over the salivary glands in vivo compared with oxybutinin. In the anaesthetised cat, intravenous tolterodine and 5-HM produced more effective inhibition of acetylcholine-induced bladder contraction than of electrically-evoked salivation. In contrast, oxybutynin showed the opposite selectivity profile.

In clinical studies involving healthy volunteers, tolterodine inhibited urodynamic bladder function, had a longer duration of effect on the bladder than on the salivary glands and a greater magnitude of effect on bladder function than on visual accommodation. The pharmacodynamic effects of tolterodine were not generally influenced by metabolic phenotype.

Pharmacokinetic Properties

The pharmacokinetic properties of tolterodine are influenced by cytochrome P450 (CYP) 2D6 polymorphism. In individuals lacking this enzyme, described as poor metabolisers, the active metabolite 5-HM cannot be formed and pharmacological effects are mediated by tolterodine alone. In contrast, the pharmacologically active moiety is represented by the sum of unbound tolterodine and 5-HM in extensive metabolisers. Nevertheless, the same dosage can be used irrespective of CYP2D6 phenotype as exposure to pharmacologically active moiety is comparable for the two subgroups.

Tolterodine is rapidly absorbed after oral administration of the immediate-release tablet formulation, reaching peak serum levels (Cmax) within 1 to 2 hours (tmax) in healthy volunteers. The effective exposure to tolterodine is unaffected by the presence of food. Tolterodine is extensively bound to plasma proteins (3.7% remaining unbound), whereas 36% of 5-HM exists as free drug.

Pharmacokinetic equivalence was demonstrated between a once daily extended-release capsule formulation of tolterodine 4mg and (immediate-release) tolterodine tablets 2mg twice daily. However, serum drug levels fluctuated less with the former preparation as evinced by median Cmax values of the active moiety that were around 75% of that observed with the twice-daily tablet formulation whereas minimum serum concentrations were 1.5-fold higher. The extended-release capsule formulation shows no evidence of ‘dose-dumping’ when administered with meals.

Tolterodine undergoes extensive first-pass hepatic metabolism, predominantly via CYP2D6-mediated oxidation and CYP 3A4-mediated N-dealkylation. With the exception of 5-HM, metabolites of tolterodine are not considered to contribute to the therapeutic effect.

Tolterodine (immediate-release tablets) has a mean systemic clearance of 44 L/h and an elimination half-life of 1.9 to 3.6 hours in extensive metabolisers. In poor metabolisers, tolterodine clearance is 5-fold lower (mean 9.0 L/h) and the elimination half-life is correspondingly longer (7.5 to 11 hours). In both poor and extensive metabolisers, the tmax and elimination half-lives of tolterodine and 5-HM were longer after administration of extended-release capsules than immediate-release tablets, consistent with a slower release of drug from the former preparation.

The clearance of tolterodine is considerably lower in patients with hepatic cirrhosis or renal impairment [creatinine clearance 10 to 30 ml/min (0.6 to 1.8 L/h)] than in healthy volunteers. In poor metabolisers, the CYP3A4 inhibitor ketoconazole appeared to reduce the clearance of tolterodine. No clinically significant drug-drug interactions were evident in patients receiving treatment with tolterodine and fluoxetine, warfarin or ethinylestradiol/levonorgestrel. Tolterodine is not expected to alter the metabolism of substrates of CYP 2D6, 2C19, 3A4 or 1A2.

Therapeutic Use

In patients with overactive bladder, 2 weeks’ treatment with immediate-release tolterodine tablets 0.5 to 4mg twice daily produced significant dose-related improvements in bladder function as evinced by increases in the volume at first contraction and maximum cystometric capacity compared with baseline.

Tolterodine immediate-release tablets 1 and 2mg twice daily improved micturition diary variables compared with baseline during 4 to 16 weeks’ treatment and consistently produced greater improvements than placebo in patients with overactive bladder. In a pooled analysis of 12-week twice daily dosage studies (n = 1120 patients), tolterodine 1 and 2mg significantly reduced micturition frequency and the incidence of urge incontinence episodes compared with placebo. Furthermore, the increase in volume voided/micturition was also significantly greater for both dosages of tolterodine than with placebo. Tolterodine 2mg twice daily was also effective in improving micturition diary variables in elderly patients (aged ≥65 years) with symptoms of overactive bladder.

In comparative studies, the efficacy of tolterodine immediate-release tablets 2mg twice daily in improving micturition diary variables was comparable with that of oxybutynin 5mg twice or 3 times daily. Statistical equivalence for reductions in micturition frequency and the incidence of urge incontinence episodes was demonstrated between tolterodine and oxybutynin after 12 weeks’ treatment. For both drugs, maximum efficacy was reached after 5 to 8 weeks of treatment.

When administered at a total daily dosage of 4 mg/day for 12 weeks, the once daily extended-release capsule formulation of tolterodine was significantly more effective than twice daily immediate-release tablets in reducing the incidence of urge incontinence episodes. Respective median reductions of 71 and 60% were reported, versus 33% in the placebo group. Compared with placebo, the active treatments had similar efficacy in significantly improving micturition frequency and the mean volume voided/micturition.

Patient perceptions of their urgency symptoms were also improved by tolterodine, administered as twice daily immediate-release tablets or once daily extended-release capsules. Significant improvements in several domains of King’s Health Questionnaire quality of life instrument were reported after 10 weeks’ treatment with tolterodine immediate-release tablets 2mg twice daily. Effects were similar to those of oxybutynin 5mg twice daily.

The clinical efficacy of tolterodine immediate-release tablets 2mg twice daily in improving micturition diary variables was maintained during long term treatment of up to 24 months’ duration.

Reports of a single 16-week noncomparative study indicate that tolterodine immediate-release tablets 2mg twice daily is also effective in treating urinary symptoms in women with mixed incontinence (urge incontinence predominating).

Tolerability

Tolterodine at dosages up to 2mg twice daily (immediate-release tablets) or 4mg once daily (extended-release capsules) was well tolerated during clinical trials of up to 24 months’ duration in patients, including the elderly, with overactive bladder. There was no difference in the nature of adverse events occurring in poor or extensive metabolisers of tolterodine.

The percentage of tolterodine-treated patients experiencing adverse events was comparable with that in placebo recipients. The most frequently reported adverse events were autonomic nervous system, gastrointestinal and general body disorders. Adverse CNS events were uncommon during placebo-controlled studies and occurred in a similar percentage of patients receiving tolterodine and placebo. No clinically significant changes in blood pressure, ECG or laboratory variables were reported during treatment with tolterodine immediate-release tablets 2mg twice daily for up to 12 months.

Dry mouth was the most commonly reported adverse event thought to be related to tolterodine treatment. The incidence of dry mouth was significantly lower in patients receiving tolterodine 1 or 2mg twice daily or placebo (24, 40 and 16%, respectively) than among oxybutynin 5mg 3 times daily recipients (78%). Additionally, the intensity of dry mouth was lower with tolterodine 1 or 2mg twice daily or placebo than with oxybutynin; severe dry mouth was reported by 2, 4, 3 and 29% of patients, respectively. Interestingly, once daily treatment with the extended-release capsule formulation of tolterodine was associated with a significant 23% lower incidence of dry mouth than with twice daily tablets (at the same total daily dosage of 4 mg/day).

Tolterodine immediate-release tablets 2mg twice daily was well tolerated during long term treatment in >1500 patients. Generally, the incidence of adverse events after 9 or 12 months’ treatment was similar to that reported in 12-week studies. Dry mouth occurred in 28 and 41% of patients, respectively, and approximately two-thirds of these episodes were mild in intensity. 70 and 62% of patients completed the 9- and 12-month studies, respectively.

Dosage and Administration

The recommended oral dosage of tolterodine immediate-release tablets in adult patients with overactive bladder is 2mg twice daily, which may be lowered to 1mg twice daily based on individual response and tolerability. Tolterodine may be administered without respect to mealtimes and no dosage adjustment is needed in the elderly. An extended-release capsule formulation of tolterodine (4mg once daily) has recently been approved by regulatory authorities.

Patients with reduced renal or hepatic function or those receiving concomitant CYP3A4 inhibitors should receive dosages of tolterodine no greater than 2 mg/day. Caution should be used when administering tolterodine to patients with clinically significant bladder outflow obstruction or gastrointestinal obstructive disorders, or to those receiving treatment for narrow-angle glaucoma. Tolterodine is contraindicated in patients with urinary retention, gastric retention or uncontrolled narrow-angle glaucoma, and should be discontinued during nursing. Tolterodine should only be used during pregnancy if the potential benefit for the mother justifies the potential risk to the fetus.

Keywords

Overactive Bladder Oxybutynin Urge Incontinence Tolterodine Antimuscarinic Agent 

References

  1. 1.
    Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477–94PubMedCrossRefGoogle Scholar
  2. 2.
    Andersson K-E, Appell R, Cardozo LD, et al. The pharmacological treatment of urinary incontinence. BJU Int 1999 Dec; 84(9): 923–47PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson K-E. The pharmacology of lower urinary tiact smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45(3): 253–308PubMedGoogle Scholar
  4. 4.
    Andersson K-E. Advances in the pharmacological control of the bladder. Exp Physiol 1999; 84(1): 195–213PubMedGoogle Scholar
  5. 5.
    Fantl JA, Newman DK, Colling J, et al. Urinary incontinence in adults: acute and chromic management. Clinical practice guideline, No. 2, 1996 Update. Rockville (MD): US Department of Human Services. Public Health Service, Agency for Health Care Policy and Research. March 1996. AHCPR Publication No. 96-0682Google Scholar
  6. 6.
    Eglen RN, Hedge SS, Watson M, et al. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 48: 531–65PubMedGoogle Scholar
  7. 7.
    Yarker YE, Goa KL, Eitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6(3): 243–62PubMedCrossRefGoogle Scholar
  8. 8.
    Chappie CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55Suppl. 5A: 33–46CrossRefGoogle Scholar
  9. 9.
    Kelleher CJ, Cadozo LD, Khullar V, et al. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988–93PubMedCrossRefGoogle Scholar
  10. 10.
    Nilvebrant L, Andersson K-E, Gillberg P-G, et al. Tolterodine — a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997 May 30; 327: 195–207PubMedCrossRefGoogle Scholar
  11. 11.
    Nilvebrant L, Gillberg P-G, Spart B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169–72PubMedCrossRefGoogle Scholar
  12. 12.
    Nilvebrandt L, Hallén B, Larsson G. Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129–36CrossRefGoogle Scholar
  13. 13.
    Gillberg P-G, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998 May 22; 349: 285–92PubMedCrossRefGoogle Scholar
  14. 14.
    Nilvebrant L, Sundquist S, Gillberg P-G. Tolterodine is not subtype (ml-m5) selective but exhibits functional bladder selectivity in vivo [abstract no. 34]. Neurourol Urodyn 1996; 15(4): 310–1Google Scholar
  15. 15.
    Naerger H, Ery CH, Nilvebrant L. Effect of tolterodine on electrically induced contactions of isolated human detrusor muscle from stable and unstable bladders [abstract]. Neurourol Urodyn 1995; 14 (Pt 5): 524–6Google Scholar
  16. 16.
    Yono M, Yoshida M, Wada Y, et al. Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol 1999 Mar 5; 368: 223–30PubMedCrossRefGoogle Scholar
  17. 17.
    Yono M, Yoshida W, Takahashi W, et al. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle. BJU Int 2000; 86: 719–25PubMedCrossRefGoogle Scholar
  18. 18.
    Brynne N, Stahl MMS, Hallén B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997 Jul; 35: 287–95PubMedGoogle Scholar
  19. 19.
    Chancellor MB. Tolterodine: selectivity for the bladder over effects on visual accommodation [abstract no. 1019]. J Urol 2000 Apr; 163 Suppl.: 229Google Scholar
  20. 20.
    Brynne N, Dalén P, Alván G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and dynamics of tolterodine. Clin Pharmacol Ther 1998 May; 63: 529–39PubMedCrossRefGoogle Scholar
  21. 21.
    Stahl MMS, Ekstiöm B, Sparf B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14(6): 647–55PubMedCrossRefGoogle Scholar
  22. 22.
    Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride and oxybutynin on the central nervous system. J Clin Pharmacol. In pressGoogle Scholar
  23. 23.
    Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999 May; 53: 990–8PubMedCrossRefGoogle Scholar
  24. 24.
    Pharmacia & Upjohn. Detrol tolterodine tartrate tablets prescribing information. Kalamazoo (MI): Pharmacia & Upjohn Co., 2001 JanGoogle Scholar
  25. 25.
    Olsson B, Szamosi J. Multiple-dose pharmacokinetics of a new once-daily, extended-release tolterodine formulation versus immediate-release tolterodine. Clin Pharmacokinet 2001; 40(3): 227–35PubMedCrossRefGoogle Scholar
  26. 26.
    Alván G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533–7PubMedCrossRefGoogle Scholar
  27. 27.
    Olsson B, Brynne N, Johansson C. Food increases the bioavailability of tolterodine but not effective exposure. J Clin Pharmacol 2001 Mar; 41(3): 298–304PubMedCrossRefGoogle Scholar
  28. 28.
    Påhlman I, Gozzi P. Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 1999 Mar; 20: 91–9PubMedCrossRefGoogle Scholar
  29. 29.
    Nilvebrant L, Påhlman I, d’Argy R. Tissue distribution of tolterodine and its metabolites: low penetration into the central nervous system. XV Meeting of the European Association of Urology, 2000 Apr 12–15, BrusselsGoogle Scholar
  30. 30.
    Olsson B, Szamosi J. Food does not influence the pharmacokinetics of a new, extended-release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001; 40(2): 135–43PubMedCrossRefGoogle Scholar
  31. 31.
    Postlind H, Danielson Å, Lindgren A, et al. Tolterodine, a novel muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998 Apr; 26(4): 289–93PubMedGoogle Scholar
  32. 32.
    Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs 1998 Jun; 55: 813–20PubMedCrossRefGoogle Scholar
  33. 33.
    Pharmacia & Upjohn. Detrol LA tolterodine tartrate extended release capsules prescribing information. Kalamazoo (MI): Pharmacia & Upjohn Company, 2000 DecGoogle Scholar
  34. 34.
    Brynne N, Böttiger Y, Hallén B, et al. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol 1999 Feb; 47: 145–50PubMedCrossRefGoogle Scholar
  35. 35.
    Brynne N, Svanström C, Åberg-Wistedt A, et al. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 1999 Oct; 48: 553–63PubMedCrossRefGoogle Scholar
  36. 36.
    Rahimy MH, Hallén B, Narang PK. Lack of tolterodine effect on warfarin safety and PK/PD in healthy volunteers. AAPS PharmSci 1998; 1 Suppl.: S147. electronic journal available from http://aapspharmaceutica.com Google Scholar
  37. 37.
    Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999 Nov; 33: 1173–6PubMedCrossRefGoogle Scholar
  38. 38.
    Abrams P, Jackson S, Mattiasson A, et al. A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia [abstract]. 26th Annual Meeting of the International Continence Society; 1996 Aug 27–30; Athens, 259Google Scholar
  39. 39.
    Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a doseranging study. Br J Urol 1998; 81: 42–8PubMedCrossRefGoogle Scholar
  40. 40.
    Van Kerrebroeck PEVA, Amarenco G, Thüroff JW, et al. Doseranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17: 499–512PubMedCrossRefGoogle Scholar
  41. 41.
    Jonas U, Höfner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997 Apr; 15: 144–51PubMedCrossRefGoogle Scholar
  42. 42.
    Diokno AC, Chancellor MB, Mitcheson HD, et al. Tolterodine (Detrol) improves incontinence and nocturia in urologist based study [abstract no. 987]. J Urol 1999 Apr; 161(4 Suppl.): 256CrossRefGoogle Scholar
  43. 43.
    Jacquetin B, Wyndaele J-J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol. In pressGoogle Scholar
  44. 44.
    Malone-Lee JG, Walsh JB, Maugourd M-F, et al. Tolterodine: a safe and effective treatment for elderly patients with overactive bladder. J Am Geriatr Soc. In pressGoogle Scholar
  45. 45.
    Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity [see comments]. J Urol 1999 May; 161: 1551–5PubMedCrossRefGoogle Scholar
  46. 46.
    Malone-Lee JG, Shaffu B, Anand C, et al. Tolterodine: superior tolerability and comparable efficacy with oxybutynin in older individuals with overactive bladder. J Urol. In pressGoogle Scholar
  47. 47.
    Abrains P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998 Jun; 81: 801–10CrossRefGoogle Scholar
  48. 48.
    Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol. J Pelvic Floor Dysfunct 1999; 10: 283–9CrossRefGoogle Scholar
  49. 49.
    Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder [abstract no. 91]. Neurourol Urodyn 1997; 16(5): 478–9Google Scholar
  50. 50.
    Chancellor M, Freedman S, Mitcheson HD, et al. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000 Feb; 19: 83–91CrossRefGoogle Scholar
  51. 51.
    van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine oncedaily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001 Mar; 57(3): 414–21PubMedCrossRefGoogle Scholar
  52. 52.
    Rabin JM. Tolterodine is rapidly effective in women with mixed incontinence [abstract]. Int J Gynaecol Obstet. In pressGoogle Scholar
  53. 53.
    Payne C, Rabin JM. Tolterodine is rapidly effective in women with mixed incontinence [abstract]. Proceedings of the 30th Annual Meeting of the International Continence Society; 2000 Aug 28–31; Tampere, FinlandGoogle Scholar
  54. 54.
    Van Kerrebroeck PEVA. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder [poster]. Proceedings of the 30th Annual Meeting of the International Continence Society; 2000 Aug 28–31; Tampere, FinlandGoogle Scholar
  55. 55.
    Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999 Apr; 83: 583–90PubMedCrossRefGoogle Scholar
  56. 56.
    Kelleher C. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder [abstract and poster]. Int Urogynecol J Pelvic Floor Dysfunct. In pressGoogle Scholar
  57. 57.
    Abrains P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging. In pressGoogle Scholar
  58. 58.
    Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol. In pressGoogle Scholar
  59. 59.
    Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 Suppl. 6A: 90–6PubMedCrossRefGoogle Scholar
  60. 60.
    Meyhoff HH, Gersrtenberg TC, Nordling J. Placebo — the drug of choice in female motor urge incontinence. Br J Urol 1983; 55: 34–7PubMedCrossRefGoogle Scholar
  61. 61.
    Kelleher CJ, Cardozo LD, Khullar V, et al. Anew questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374–9PubMedCrossRefGoogle Scholar
  62. 62.
    Drutz HP. Tolterodine is effective amd well tolerated during long-term use in patients with overactive bladder [abstract]. Int J Gynaecol Obstet. In pressGoogle Scholar
  63. 63.
    Malavaud B, Bagheri H, Senard JM, et al. Visual hallucinations at the onset of tolterodine treatment in a patient with a highlevel spinal cord injury. BJU Int 1999 Dec; 84: 1109PubMedCrossRefGoogle Scholar
  64. 64.
    Pharmacia & Upjohn. Detrusitol. In: Walker G, compiler. ABPI Compendium of data sheets and summary of product characteristics 1999–2000. London: Datapharm Publications Ltd, 2000: 1188–9Google Scholar
  65. 65.
    Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18(1): 84–112PubMedGoogle Scholar
  66. 66.
    Abrains P, Wein AJ, editors. The overactive bladder: a widespread and treatable condition. Stockholm: Erik Sparre Medical AB, 1998Google Scholar
  67. 67.
    Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil 1999; 44: 56–66Google Scholar
  68. 68.
    Lenderking WR, Nackley JE, Anderson RB, et al. A review of the quality of life aspects of urinary urge incontinence. Pharmaco Economics 1996; 9(1): 11–23CrossRefGoogle Scholar
  69. 69.
    Wyman JE, Harkins SW, Choi SC, et al. Psychosocial impact of urinary incontinence in women. Obstet Gynecol 1987; 70 (3 Pt 1): 378–81PubMedGoogle Scholar
  70. 70.
    Kobelt-Nguyen G, Johannesson M, Marrasson A, et al. Correlation between symptoms of urge incontinence and scores of a generic quality of life instrument (SE36) and health status measurements (EUROQOL) and between changes in symptoms and QoL scores [abstract no. 195]. Annual Meeting of the International Continence Society; 1997 Sep 23–26; YokohamaGoogle Scholar
  71. 71.
    Johannesson M, O’Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 88: 557–62Google Scholar
  72. 72.
    O’Conor RM, Johannesson M, Hass SL, et al. Urge incontinence: quality of life and patients’ valuation of symptom reduction. Pharmacoeconomics 1998; 14(5): 531–9PubMedCrossRefGoogle Scholar
  73. 73.
    AHCPR Urinary Incontinence in Adults Guideline Update Panel. Managing acute and chronic urinary incontinence. Am Fam Physician 1996 Oct; 54: 1661–72Google Scholar
  74. 74.
    National Institutes of Health Consensus Development Conference. Urinary incontinence in adults. J Am Geriatr Soc 1989; 261: 2685–90Google Scholar
  75. 75.
    Thuroff JW, Bunke B, Ebner A, et al. Randomized, doubleblind, multicenter tirai on treatment of frequency, urgency and incontinence related to detrusor hyperactivity; oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 531–9Google Scholar
  76. 76.
    Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988; 140: 47–50PubMedGoogle Scholar
  77. 77.
    Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000; 12(2): 149–55CrossRefGoogle Scholar
  78. 78.
    Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161: 1809–12PubMedCrossRefGoogle Scholar
  79. 79.
    Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95: 718–21PubMedCrossRefGoogle Scholar
  80. 80.
    Ditropan XL needs longer trial to support superiority claim for dry mouth. Pharm Approv Monthly 1999 Apr; 161 Suppl.: 26–30Google Scholar
  81. 81.
    Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997 Nov 22; 315: 1363–2364PubMedCrossRefGoogle Scholar
  82. 82.
    Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment of older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 8–13PubMedGoogle Scholar
  83. 83.
    Chutka DS, Takahashi PY. Urinary incontinence in the elderly: drug treatment options. Drugs 1998 Oct; 56: 587–95PubMedCrossRefGoogle Scholar
  84. 84.
    Oxybutynin hydrochloride. British National Formulary 40. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2000 Sep: 382–3Google Scholar
  85. 85.
    Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med 1997; 157: 1531–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations